SAN DIEGO, Oct. 2 /PRNewswire/ -- Ceregene, Inc., announced today that it has appointed Joao Siffert, M.D. to the position of vice president and chief medical officer. Dr. Siffert will be responsible for Ceregene's clinical programs in Parkinson's and Alzheimer's diseases and will report to Raymond T. Bartus, Ph.D., Ceregene's senior vice president of clinical and preclinical R&D and chief operating officer.
"Joao brings a wealth of experience in clinical development to Ceregene as he has managed all aspects of clinical trials from Phase 1-4 and product launch in neurological areas, which will be highly relevant to us as we continue pursuing our clinical programs for Parkinson's disease and Alzheimer's disease," stated Jeffrey M. Ostrove, Ph.D., president and chief executive officer of Ceregene. "Ceregene is currently conducting a controlled Phase 2 trial of CERE-120 for Parkinson's disease, and Joao's contributions will be critical as we move this product into late stage trials in the coming years."
Dr. Siffert previously served as the chief medical officer at Avera
Pharmaceuticals, a CNS specialty pharma company. Prior to joining Avera,
Dr. Siffert held positions with Pfizer as the worldwide medical team leader
in areas of pain and epilepsy of various products including Relpax, Lyrica
and Neurontin. He was also instrumental in the Phase 3b/4 program
development and global launch of Lyrica. Prior to Pfizer, Dr. Siffert held
academic positions at Beth Israel Medical Center, where he served as
director of the Adult Neuro-Oncology program, and Albert Einstein College
of Medicine, where he was assistant professor of Neurology. During his
tenure at Beth Israel, Dr. Siffert was actively involved in clinical
research of novel therapies for patients with brain and spinal cord tumors.
He completed residencies in pediatrics at New York University School of
Medicine and in neurology at Harvard Medical School. Dr. Siffert was
certified by the American Board
Copyright©2007 PR Newswire.
All rights reserved